NMRA|EPS -$0.35|Web Loss $59.4M
Neumora Therapeutics is a clinical-stage biopharmaceutical firm targeted on creating next-generation therapies for mind ailments.
Based mostly on the offered monetary statements, the corporate didn’t report any income for 2024 or 2025. The fundamental and diluted internet loss per share (EPS) was $(1.45) for the total yr 2025, an enchancment from $(1.53) in 2024. For the fourth quarter of 2025, the EPS was $(0.35).
Neumora reported a complete internet lack of $236.9 million for the total yr 2025. As of December 31, 2025, the corporate held $182.5 million in money, money equivalents, and marketable securities, which is anticipated to fund its operations into the third quarter of 2027.
This text was generated with the help of AI know-how and reviewed for accuracy. AlphaStreet could obtain compensation from corporations talked about on this article. This content material is for informational functions solely and shouldn’t be thought of funding recommendation.
